Clinical Trials - April 8, 2022
Elypta launches multi-cancer early detection study
Elypta has announced the launch of its second clinical study intended to validate the diagnostic performance of GAGomes – the complete profile of human glycosaminoglycans – as metabolic biomarkers for Multi-Cancer Early Detection (MCED). This study, LEVANTIS-0093A (LEV93A), aims to detect any-type cancer in adults at high risk of developing cancer due to significant smoking […]
Uncategorized - April 7, 2022
Elicera published scientific article describing the mechanism-of-action of iTANK
Elicera Therapeutics have announced the publication of a scientific article describing the mechanism-of-action of the company’s universal CAR T-cell enhancement technology platform iTANK in Nature Biomedical Engineering. Proof-of-concept data presented in the publication also indicate that the iTANK-platform is universally compatible with other CAR T-cell therapies, states the company in a press release. The iTANK-platform […]
Intellectual Property - April 28, 2021
Elicera Therapeutics files a patent application
Elicera Therapeutics has filed a patent application to protect the development of its drug candidate ELC-201. ELC-201 is the second oncolytic virus in Elicera Therapeutic’s product portfolio. It is based on an adenovirus that has been genetically modified in a way that makes the treatment applicable to most cancers and the patent application protects the […]
